Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.
about
Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Continuation of gefitinib plus ...... tinib without T790M mutations.
@en
Continuation of gefitinib plus ...... tinib without T790M mutations.
@nl
type
label
Continuation of gefitinib plus ...... tinib without T790M mutations.
@en
Continuation of gefitinib plus ...... tinib without T790M mutations.
@nl
prefLabel
Continuation of gefitinib plus ...... tinib without T790M mutations.
@en
Continuation of gefitinib plus ...... tinib without T790M mutations.
@nl
P2093
P2860
P356
P1476
Continuation of gefitinib plus ...... tinib without T790M mutations.
@en
P2093
Caicun Zhou
Heyong Wang
Shengxiang Ren
Shijia Zhang
Xiaoxia Chen
P2860
P304
P356
10.21037/JTD.2017.07.107
P577
2017-09-01T00:00:00Z